CAR-T treatment is given ‘historic’ first approval by FDA

04:34 EDT 31 Aug 2017 | Pharmafile

Novartis has received approval for its CAR-T treatment of paediatric and young adults with a form of acute lymphoblastic leukaemia (ALL). The approval marks a breakthrough for this type of treatment that reengineers the body’s own immune system to combat cancer and had the FDA referencing its decision as ‘historic’.

It was an approval that was widely expected, after an FDA advisory committee gave the drug the thumbs up but the decision has been arrived at sooner than expected. It means hundreds of patients could be eligible for the treatment immediately.

read more

Original Article: CAR-T treatment is given ‘historic’ first approval by FDA


More From BioPortfolio on "CAR-T treatment is given ‘historic’ first approval by FDA"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...